REPLIGEN CORP Accounts Receivable, Allowance for Credit Loss, Writeoff
REPLIGEN CORP (RGEN) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $135.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2025-03-14
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for the quarter ending 2020-12-31 was $65.00K.
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for the quarter ending 2020-06-30 was $37.00K.
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for fiscal 2024 was $135.00K, a 64.63% increase from fiscal 2023.
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for fiscal 2023 was $82.00K, a 34.92% decline from fiscal 2022.
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for fiscal 2022 was $126.00K, a 27.17% decline from fiscal 2021.
- REPLIGEN CORP accounts receivable, allowance for credit loss, writeoff for fiscal 2021 was $173.00K, a 69.61% increase from fiscal 2020.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|
| 2024-12-31 | $135.00K 10-K · filed 2025-03-14 | |
| 2023-12-31 | $82.00K 10-K · filed 2025-03-14 | |
| 2022-12-31 | $126.00K 10-K/A · filed 2024-11-18 | |
| 2021-12-31 | $173.00K 10-K · filed 2023-02-22 | |
| 2020-12-31 | $65.00K 10-K · filed 2021-02-24 | $102.00K 10-K · filed 2022-02-17 |
| 2020-06-30 | $37.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |